Literature DB >> 22248322

Familial and acquired hemophagocytic lymphohistiocytosis.

G E Janka1.   

Abstract

Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening syndrome in which an uncontrolled and ineffective immune response, triggered in most cases by infectious agents, leads to severe hyperinflammation. Familial forms of HLH (FHL), which are increasingly found also in adolescents and adults, are due to genetic defects leading to impaired function of natural killer cells and cytotoxic T cells. These mutations occur either in the perforin gene or in genes important for the exocytosis of cytotoxic granules. Cytotoxic granules contain perforin and granzymes, which induce apoptosis upon entering (infected) target cells. Additionally, perforin is important for the downregulation of the immune response. Acquired forms of HLH are encountered in association with (usually) viral infections, autoinflammatory/autoimmune diseases, malignant diseases, and acquired immune deficiency states (e.g., after organ transplantation). Treatment of HLH includes immune-suppressive and immune-modulatory agents, cytostatic drugs, and biological response modifiers. For patients with FHL, stem cell transplantation is indicated and can be curative.

Entities:  

Mesh:

Year:  2012        PMID: 22248322     DOI: 10.1146/annurev-med-041610-134208

Source DB:  PubMed          Journal:  Annu Rev Med        ISSN: 0066-4219            Impact factor:   13.739


  156 in total

Review 1.  Infectious Mononucleosis.

Authors:  Samantha K Dunmire; Kristin A Hogquist; Henry H Balfour
Journal:  Curr Top Microbiol Immunol       Date:  2015       Impact factor: 4.291

Review 2.  Perforin and granzymes: function, dysfunction and human pathology.

Authors:  Ilia Voskoboinik; James C Whisstock; Joseph A Trapani
Journal:  Nat Rev Immunol       Date:  2015-06       Impact factor: 53.106

Review 3.  [Histiocytosis in the dermatological context of the new classification].

Authors:  C Lang; J-T Maul; L Krähenbühl; F Dimitriou; R Dummer
Journal:  Hautarzt       Date:  2019-09       Impact factor: 0.751

4.  Regulation of perforin activation and pre-synaptic toxicity through C-terminal glycosylation.

Authors:  Imran G House; Colin M House; Amelia J Brennan; Omer Gilan; Mark A Dawson; James C Whisstock; Ruby Hp Law; Joseph A Trapani; Ilia Voskoboinik
Journal:  EMBO Rep       Date:  2017-08-14       Impact factor: 8.807

5.  The Nobel Path of Cellular Proteins.

Authors:  Joel C Eissenberg; William S Sly
Journal:  Mo Med       Date:  2014 Mar-Apr

6.  A novel pathogenic variant in PRF1 associated with hemophagocytic lymphohistiocytosis.

Authors:  Camilo Andrés Pérez Romero; Isaura Pilar Sánchez; Sebastian Gutierrez-Hincapié; Jesús A Álvarez-Álvarez; Jaime Andres Pereañez; Rodrigo Ochoa; Carlos Enrique Muskus-López; Ruth G Eraso; Carolina Echeverry; Catalina Arango; José Luis Franco Restrepo; Claudia Milena Trujillo-Vargas
Journal:  J Clin Immunol       Date:  2015-05-15       Impact factor: 8.317

7.  Synaptobrevin2 is the v-SNARE required for cytotoxic T-lymphocyte lytic granule fusion.

Authors:  Ulf Matti; Varsha Pattu; Mahantappa Halimani; Claudia Schirra; Elmar Krause; Yuanyuan Liu; Lisa Weins; Hsin Fang Chang; Raul Guzman; Jenny Olausson; Marc Freichel; Frank Schmitz; Mathias Pasche; Ute Becherer; Dieter Bruns; Jens Rettig
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

Review 8.  The genetics of macrophage activation syndrome.

Authors:  Grant S Schulert; Randy Q Cron
Journal:  Genes Immun       Date:  2020-04-15       Impact factor: 2.676

9.  Scrub typhus associated with hemophagocytic lymphohistiocytosis: A report of six pediatric patients.

Authors:  Yingkang Jin; Li Huang; Huifeng Fan; Gen Lu; Yi Xu; Zhiyuan Wu
Journal:  Exp Ther Med       Date:  2016-09-06       Impact factor: 2.447

10.  Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.

Authors:  Stephan A Grupp; Michael Kalos; David Barrett; Richard Aplenc; David L Porter; Susan R Rheingold; David T Teachey; Anne Chew; Bernd Hauck; J Fraser Wright; Michael C Milone; Bruce L Levine; Carl H June
Journal:  N Engl J Med       Date:  2013-03-25       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.